Cardiovascular Drugs and Therapy

, Volume 21, Issue 5, pp 375–388

Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes

  • Stanley G. Rockson
  • Emil M. deGoma
  • Gregg C. Fonarow
Review

Abstract

Introduction

Patients with a history of acute coronary syndrome are particularly susceptible to further vascular or ischemic events. Effective secondary prevention following acute coronary syndrome requires multiple medications targeting the different mechanisms of atherothrombosis. The 2002 American College of Cardiology/American Heart Association guidelines for the management of unstable angina and non ST-segment myocardial infarction and the 2004 guidelines for ST-segment myocardial infarction assign priority to the long-term administration of four critical classes of drugs: antiplatelet agents, in particular aspirin and clopidogrel, β-blockers, angiotensin-converting enzyme inhibitors, and statins.

Conclusions

Despite clinical trial evidence demonstrating their ability to reduce cardiovascular morbidity and mortality, available preventive pharmacotherapies remain underutilized. Suboptimal compliance with current recommendations, as with other management guidelines, arises from a host of entrenched physician, patient, and system-related factors. Optimal management of acute coronary syndrome acknowledges a continuum of care in which acute stabilization represents a single important component. Early, in-hospital implementation of secondary preventive measures reinforces the continuum of care approach, promoting a successful transition from treatment to prevention, inpatient to outpatient management, and, when appropriate, subspecialist to generalist care.

Key words

acute coronary syndromes quality improvement guidelines 

References

  1. 1.
    Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671–719.PubMedCrossRefGoogle Scholar
  2. 2.
    American Heart Association. Heart disease and stroke statistics—2007 update (American Heart Association); 2007 (accessed at http://www.circ.ahajournals.org).
  3. 3.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.CrossRefGoogle Scholar
  4. 4.
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57.Google Scholar
  5. 5.
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Merz CN, Rozanski A, Forrester JS. The secondary prevention of coronary artery disease. Am J Med 1997;102:572–81.PubMedCrossRefGoogle Scholar
  7. 7.
    ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina); 2002 (accessed at http://www.acc.org/clinical/guidelines/unstable/unstable.pdf).
  8. 8.
    Smith SC Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Chesterman CN, Berndt MC. Platelet and vessel wall interaction and the genesis of atherosclerosis. Clin Haematol 1986;15:323–53.PubMedGoogle Scholar
  10. 10.
    DiCorleto PE. Cellular mechanisms of atherogenesis. Am J Hypertens 1993;6:314S–8S.PubMedGoogle Scholar
  11. 11.
    Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005;96:612–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Cassar K, Bachoo P, Brittenden J. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg 2003;25:6–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.CrossRefGoogle Scholar
  16. 16.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81–106.Google Scholar
  17. 17.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.PubMedCrossRefGoogle Scholar
  18. 18.
    Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–89.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Shah KB, Gottlieb SS. Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Curr Heart Fail Rep 2004;1:161–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730–7.PubMedGoogle Scholar
  25. 25.
    Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart 2000;83:76–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Mancini GB, Henry GC, Macaya C, O’Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258–65.PubMedGoogle Scholar
  29. 29.
    Prasad A, Husain S, Quyyumi AA. Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol 1999;84:1–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997;96:442–7.PubMedGoogle Scholar
  31. 31.
    Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin–angiotensin system and fibrinolytic function. Circulation 1993;87:1969–73.PubMedGoogle Scholar
  32. 32.
    Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001;37:1565–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Soejima H, Ogawa H, Yasue H, Kaikita K, Takazoe K, Nishiyama K, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999;34:983–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001;87:25C–32C.PubMedCrossRefGoogle Scholar
  35. 35.
    Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598–604.PubMedCrossRefGoogle Scholar
  36. 36.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145–53.PubMedCrossRefGoogle Scholar
  37. 37.
    Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058–68.PubMedCrossRefGoogle Scholar
  39. 39.
    Dagenais GR, Pogue J, Fox KA, Simoons ML, Yusuf S. Angiotensin-convertin enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926–33.Google Scholar
  41. 41.
    Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276–83.PubMedGoogle Scholar
  42. 42.
    Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002;105:1756–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001;103:2248–53.PubMedGoogle Scholar
  44. 44.
    Szczeklik A, Musial J, Undas A, Gajewski P, Góra P, Swadźba J, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999;33:1286–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992;64:196–201.PubMedCrossRefGoogle Scholar
  46. 46.
    Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519–24.PubMedGoogle Scholar
  47. 47.
    Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178–84.PubMedGoogle Scholar
  48. 48.
    Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227–33.PubMedGoogle Scholar
  49. 49.
    Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pascuala R, Hernández G, Díaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.Google Scholar
  51. 51.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.PubMedCrossRefGoogle Scholar
  52. 52.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  53. 53.
    Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–8.PubMedCrossRefGoogle Scholar
  54. 54.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35.PubMedCrossRefGoogle Scholar
  55. 55.
    Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Chyrchel M, Rakowski T, Rzeszutko L, Legutko J, Dziewierz A, Dubiel JS, et al. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol 2006;64:1357–62; discussion 63.PubMedGoogle Scholar
  57. 57.
    Brady AJ, Pittard JB, Grace JF, Robinson PJ. Clinical assessment alone will not benefit patients with coronary heart disease: failure to achieve cholesterol targets in 12,045 patients—the Healthwise II study. Int J Clin Pract 2005;59:342–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180–9.PubMedCrossRefGoogle Scholar
  59. 59.
    EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72.CrossRefGoogle Scholar
  60. 60.
    Yan AT, Tan M, Fitchett D, Chow CM, Fowlis RA, McAvinue TG, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol 2004;94:25–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Pearson TA. The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study: attainment of goals for comprehensive risk reduction in patients with coronary disease in the US. J Am Coll Cardiol 1998;31:186A.CrossRefGoogle Scholar
  62. 62.
    Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67.PubMedCrossRefGoogle Scholar
  64. 64.
    Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997;277:1281–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 2003;163:2576–82.PubMedCrossRefGoogle Scholar
  66. 66.
    Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257–61.PubMedCrossRefGoogle Scholar
  67. 67.
    Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol 2000;85:10A–7A.PubMedCrossRefGoogle Scholar
  69. 69.
    Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819–22.PubMedCrossRefGoogle Scholar
  70. 70.
    McCarthy M. US heart-guidelines strategy makes promising start. Lancet 2001;358:1618.PubMedCrossRefGoogle Scholar
  71. 71.
    LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004;164:203–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Mehta RH, Montoye CK, Gallogly M, Baker P, Blount A, Faul J, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287:1269–76.PubMedCrossRefGoogle Scholar
  73. 73.
    Eagle KA, Montoye CK, Riba AL, DeFranco AC, Parrish R, Skorcz S, et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction. The American College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005;46:1242–8.PubMedCrossRefGoogle Scholar
  74. 74.
    CRUSADE 2004 Quarter 1 results. 2004 (accessed at http://www.crusadeqi.com/main/ecab/slides/CRUSADEResults2004Q1.ppt).
  75. 75.
    Peterson ED, Roe MT, Mulgund J, DeLong ER, Lytle BL, Brindis RG, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006;295:1912–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation 2001;103:2768–70.PubMedGoogle Scholar
  77. 77.
    Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96:183–91.PubMedGoogle Scholar
  78. 78.
    Critical Pathway for UA/NSTEMI. 2007 (accessed at http://www.med.ucla.edu/champ).

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Stanley G. Rockson
    • 1
  • Emil M. deGoma
    • 1
  • Gregg C. Fonarow
    • 2
  1. 1.Division of Cardiovascular Medicine, Falk Cardiovascular Research CenterStanford UniversityStanfordUSA
  2. 2.Ahmanson-UCLA Cardiomyopathy CenterUniversity of California, Los Angeles Medical CenterLos AngelesUSA

Personalised recommendations